AGILE: a global, randomized, double-blind, phase 3 study of ivosidenib + azacitidine versus placebo + azacitidine in patients with newly diagnosed acute myeloid leukemia with an IDH1 mutation (2021)
- Authors:
- Autor USP: RODRIGUES, RODRIGO DO TOCANTINS CALADO DE SALOMA - FMRP
- Unidade: FMRP
- DOI: 10.1182/blood-2021-147805
- Subjects: LEUCEMIA MIELOIDE; MUTAÇÃO
- Language: Inglês
- Imprenta:
- Publisher place: Washington
- Date published: 2021
- Source:
- Conference titles: ASH Annual Meeting Abstracts
- Este periódico é de acesso aberto
- Este artigo NÃO é de acesso aberto
-
ABNT
MONTESINOS, Pau et al. AGILE: a global, randomized, double-blind, phase 3 study of ivosidenib + azacitidine versus placebo + azacitidine in patients with newly diagnosed acute myeloid leukemia with an IDH1 mutation. Blood. Washington: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. Disponível em: https://doi.org/10.1182/blood-2021-147805. Acesso em: 26 jan. 2026. , 2021 -
APA
Montesinos, P., Recher, C., Vives, S., Zarzycka, E., Wang, J., Bertani, G., et al. (2021). AGILE: a global, randomized, double-blind, phase 3 study of ivosidenib + azacitidine versus placebo + azacitidine in patients with newly diagnosed acute myeloid leukemia with an IDH1 mutation. Blood. Washington: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. doi:10.1182/blood-2021-147805 -
NLM
Montesinos P, Recher C, Vives S, Zarzycka E, Wang J, Bertani G, Heuser M, Calado RT, Schuh AC, Yeh S-P, Daigle SR, Hui J, Zhang V, Pandya SS, Gianolio D, Botton S de, Döhner H. AGILE: a global, randomized, double-blind, phase 3 study of ivosidenib + azacitidine versus placebo + azacitidine in patients with newly diagnosed acute myeloid leukemia with an IDH1 mutation [Internet]. Blood. 2021 ; 138 697-697.[citado 2026 jan. 26 ] Available from: https://doi.org/10.1182/blood-2021-147805 -
Vancouver
Montesinos P, Recher C, Vives S, Zarzycka E, Wang J, Bertani G, Heuser M, Calado RT, Schuh AC, Yeh S-P, Daigle SR, Hui J, Zhang V, Pandya SS, Gianolio D, Botton S de, Döhner H. AGILE: a global, randomized, double-blind, phase 3 study of ivosidenib + azacitidine versus placebo + azacitidine in patients with newly diagnosed acute myeloid leukemia with an IDH1 mutation [Internet]. Blood. 2021 ; 138 697-697.[citado 2026 jan. 26 ] Available from: https://doi.org/10.1182/blood-2021-147805 - Telomere shortening in hepatocyte proliferation and predisposition to alcohol-induced steatosis
- Telomerase enzyme deficiency promotes metabolic dysfunction in murine hepatocytes upon dietary stress
- Telomere dynamics in iPS cells derived from human patients with telomerase mutations
- Predictors of early mortality after rabbit antithymocyte globulin as first-line treatment in severe aplastic anemia
- Células reprogramadas. [Depoimento a Hérika Dias e Luis Ribeiro]
- A mutation in the CCAAT box of the TERC promoter region causes telomere disease
- Telomeres in disease
- Immunologic aspects of hypoplastic myelodysplastic syndrome
- Clinical profile, biological markers, and comorbidity index as predictors of transplant-related mortality after allo-HSCT
- Treatment of inherited bone marrow failure syndromes beyond transplantation
Informações sobre o DOI: 10.1182/blood-2021-147805 (Fonte: oaDOI API)
Download do texto completo
| Tipo | Nome | Link | |
|---|---|---|---|
 |
003251243.pdf |
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
